This is a randomized, placebo-controlled, double-blind, 3-arm, single-center, phase IIa,
parallel study to assess the efficacy, safety, and tolerability of topically applied 2.5%, 5%
GM-XANTHO plus standard of care in patients with stage II or stage III pressure ulcer.